WallStSmart

Cytosorbents Crp (CTSO)vsMedtronic PLC (MDT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 95856% more annual revenue ($35.48B vs $36.98M). MDT leads profitability with a 13.0% profit margin vs -27.8%. MDT earns a higher WallStSmart Score of 56/100 (C).

CTSO

Avoid

28

out of 100

Grade: F

Growth: 4.0Profit: 2.0Value: 5.0Quality: 5.0

MDT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.5Value: 7.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CTSO.

MDTSignificantly Overvalued (-255.7%)

Margin of Safety

-255.7%

Fair Value

$24.34

Current Price

$87.89

$63.55 premium

UndervaluedFair: $24.34Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CTSO0 strengths · Avg: 0/10

No standout strengths identified

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$110.62B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$2.30B8/10

Generating 2.3B in free cash flow

Areas to Watch

CTSO4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$41.45M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-93.3%2/10

ROE of -93.3% — below average capital efficiency

Free Cash FlowQuality
$-2.59M2/10

Negative free cash flow — burning cash

MDT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : CTSO

Revenue growth of 10.1% demonstrates continued momentum.

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin.

Bear Case : CTSO

The primary concerns for CTSO are EPS Growth, Market Cap, Return on Equity.

Bear Case : MDT

The primary concerns for MDT are EPS Growth.

Key Dynamics to Monitor

CTSO profiles as a turnaround stock while MDT is a value play — different risk/reward profiles.

CTSO carries more volatility with a beta of 1.40 — expect wider price swings.

CTSO is growing revenue faster at 10.1% — sustainability is the question.

MDT generates stronger free cash flow (2.3B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (56/100 vs 28/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cytosorbents Crp

HEALTHCARE · MEDICAL DEVICES · USA

Cytosorbents Corporation, a critical care focused immunotherapy company, is dedicated to the research, development and commercialization of medical devices with its blood purification technology platform incorporating proprietary adsorbent and porous polymer technology. The company is headquartered in Monmouth Junction, New Jersey.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Want to dig deeper into these stocks?